Telix Pharmaceuticals Ltd — Director's Dealing 2017

Nov 14, 2017

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.

Name of entity Telix Pharmaceuticals Limited ABN 85 616 620 369

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Oliver Buck
Date of appointment	16 January 2017

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

Not applicable.

• See chapter 19 for defined terms.

Appendix 3X Page 1

11/3/2002

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest. Evo-partners GmbH of which Oliver Buck is a director and shareholder.	Number & class of Securities 1,057,500 fully paid ordinary shares. 495,000 unlisted share options with an exercise price of $0.85 per option and an expiry date of 14 October 2021, granted subsequent to shareholder approval at the EGM held 13 October 2017.

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Isotopen Technologien München (ITM) AG is a leading supplier of diagnostic and therapeutic isotopes for nuclear medicine. Telix has a global supply agreement with ITM for the procurement of 177Lu, a key component of Telix’s therapeutic products.
Nature of interest	Oliver Buck is a member of the Supervisory Board and has a has a material personal interest in ITM.
Name of registered holder (if issued securities)	Not applicable
No. and class of securities to which interest relates	Not applicable

• See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002